Related Experiment Video
Updated: Jul 17, 2026

Autologous Blood Injection to Model Spontaneous Intracerebral Hemorrhage in Mice
Published on: August 24, 2011
Extradural hematoma management: A case-control study with historical controls reassessing the 'zero mortality' goal
N Marchesini1,2, L Rossi3, E Saiu3
1Leiden University Medical Center (LUMC), Leiden, the Netherlands.
Introduction:
Extradural hematoma (EDH) remains a significant cause of mortality following traumatic brain injury (TBI), although fatality rates have declined. This study examines whether improvements in a regional trauma and neurosurgical care system over four decades have enabled the achievement of the long-standing goal of "zero mortality" in surgically treated EDH.
Research Question:
Has the evolution of a regional trauma and neurosurgical care system over four decades reduced mortality and moved towards the 'zero mortality' goal in surgically treated extradural hematomas?
Materials And Methods:
We retrospectively reviewed all patients who underwent surgery for EDH at our institution between 2011 and 2021. Demographic, clinical, and radiological data were collected and compared in a case-control design with a historical cohort treated at the same center in the early 1980s, when the "zero mortality" concept was first proposed.
Results:
Among 85 contemporary cases, most patients were aged 41-61 years (previously 11-20), and falls were the leading cause of injury (55% vs. 50% due to road traffic accidents; p = 0.007). Direct presentations increased (65% vs. 33%; p < 0.001), and 96% arrived within 6 h (vs. 65%; p < 0.001). Surgery within 6 h occurred in 68% of cases. Referred patients experienced significantly longer delays. Craniotomy was performed in 94% of cases. In-hospital mortality was 2.4% (vs. 4.7%).
Discussion And Conclusions:
Although system-wide improvements have reduced mortality, the "zero mortality" target remains unmet. Delays in referral and triage continue to pose challenges, particularly in complex or rapidly evolving cases.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups
Cancer Survival Analysis

